Table 1.

Ranking of barriers and facilitators, results from the pilot survey

Rank	Barriers	Facilitators
1	The clinical utility of WGS compared to TGPs will not be demonstrated sufficiently.	The clinical utility of WGS compared to TGPs has been demonstrated sufficiently.
2	The turnaround time of WGS will remain significantly longer compared with that of TGPs.	WGS will be included in basic health insurance.
3	The price of WGS will remain too high.	The price of WGS will drop significantly.
4	A technology that is superior in terms of cost and/or clinical utility compared to WGS will become available.	The interpretation of WGS results will become as easy as TGP results.
5	The interpretation of WGS results will not become easier.	The turnaround time of WGS will decrease and become equal to that of TGPs.
6	Fresh frozen biopsies will remain the only reliable source of DNA for WGS.	Other type of biopsies can be used for WGS, for example, liquid biopsies and FFPE biopsies.
7	WGS will not become part of basic health insurance.	No other technology that would compete with WGS will become available.

The ranked barriers and facilitators are ordered from most important to least important

WGS Whole Genome Sequencing, TGP Targeted Gene Panel, DNA deoxyribonucleic acid, FFPE Formalin-Fixed Paraffin-Embedded